Developing inhibitors targeting key enzymes in lactate metabolism, such as LDHA, can reduce lactate production by tumor cells, thereby improving the tumor microenvironment and enhancing the infiltration and killing ability of immune cells against tumors. The gene discussed is LDHA; the disease is neoplasm.